Expression of p130cas, E-cadherin and β-catenin and their correlation with clinicopathological parameters in non-small cell lung cancer: p130cas over-expression predicts poor prognosis

Abstract

Expression of p130cas, E-cadherin andAbstract: p130cas (p130 Crk-associated substrate) is a scaffolding protein and plays an important role in regulating focal adhesion and driving cell migration. Also, the destruction of the E-cadherin/b-catenin adhesive complex is one of the changes that characterizes the invasive phenotype of tumors. The aim of this study is to evaluate the role of p130cas, E-cadherin, and b-catenin expression in patients with non-small cell lung cancer (NSCLC). We examined the expression of p130cas, E-cadherin, and b-catenin in 105 lung cancer tissues and paired adjacent normal lung tissues using immunohistochemistry. The overexpression of p130cas was observed in 61.9% (65/105) of lung cancer samples. The overexpression of p130cas was correlated with abnormal expression of E-cadherin and b-catenin (p = 0.002 and p = 0.006, respectively). Chi-square test showed that the overexpression of p130cas correlated positively with lymph node metastasis and high TNM stage. The LogRank test revealed that the mean survival time of patients with p130cas overexpression (36.31 ± 5.66 months) was markedly shorter than that of those with p130cas normal expression (60.57 ± 6.95 months). Multivariable analysis indicated p130cas overexpression (p < 0.001) to be an independent significant prognostic factor for NSCLC patients' survival. These results indicate that p130cas may impact a variety of clinicopathological features of NSCLC and may influence the prognosis of lung cancer patients.

Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use?

“…Controls migration, apoptosis, cell cycle and differentiation [102,103] Poor prognosis 105 < 0.001 < 0.001 [104] Huang et al Chao et al…”

BCAR1 promotes proliferation and cell growth in lung adenocarcinoma via upregulation of POLR2A

“…Furthermore, BCAR1 is found to be highly expressed in lung cancer cell lines 11 . Cell growth arrest, inhibition of cell migration, and EMT can occur following BCAR1‐KO in lung cancer cells 13, 20 …”

“…Moreover, BCAR1 has been considered as a new potential molecular marker for lung cancer. 19 High expression of BCAR1 predicts poor prognosis in lung cancer patients 11,12,20 and is associated with lymph node metastasis, distant organ metastasis, 4,20 and chemotherapy resistance in lung cancer. 4 Furthermore, BCAR1 is found to be highly expressed in lung cancer cell lines.…”

“…11 Cell growth arrest, inhibition of cell migration, and EMT can occur following BCAR1-KO in lung cancer cells. 13,20 However, to our knowledge, no study has previously investigated the role of BCAR1 in lung cancer cell proliferation. Moreover, the proteins that interact with BCAR1 remain unclear.…”

Altered protein expression profile associated with phenotypic changes in lung fibroblasts co-cultured with gold nanoparticle-treated small airway epithelial cells

“…PXN is a focal adhesion (FA) associated adapter protein which regulates cell spreading and motility [31]. While PXN is believed to play a role in targeting vinculin to FAs, BCAR1 (also known as p130Cas), has been reported to be important in controlling spreading and motility of cancer cells through regulating FA [32,33]. Cav-1 is known to mediate cancer metastasis and reports have suggested that upregulation of Cav-1 induced cell attachment [34e36].…”